ID | 64213 |
フルテキストURL | |
著者 |
Kawashima, Shusuke
Department of Dermatology, Graduate School of Medicine, Chiba University
Togashi, Yosuke
Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
|
抄録 | Immune checkpoint inhibitors (ICIs) have contributed significantly to the treatment of various types of cancer, including skin cancer. However, not all patients respond; some patients do not respond at all (primary resistance), while others experience recurrence after the initial response (acquired resistance). Therefore, overcoming ICI resistance is an urgent priority. Numerous ICI resistance mechanisms have been reported. They are seemingly quite complex, varying from patient to patient. However, most involve T cell activation processes, especially in the tumor microenvironment (TME). ICIs exert their effects in the TME by reactivating suppressed T cells through inhibition of immune checkpoint molecules, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1). Thus, this review focuses on the resistance mechanisms based on the T cell activation process. Here, we classify the main mechanisms of ICI resistance into three categories based on: (1) antigen recognition, (2) T cell migration and infiltration, and (3) effector functions of T cells. By identifying and understanding these resistance mechanisms individually, including unknown mechanisms, we seek to contribute to the development of novel treatments to overcome ICI resistance.
|
キーワード | immune checkpoint inhibitors
tumor microenvironment
antitumor immunity
primary resistance
acquired resistance
|
備考 | This is the peer reviewed version of the following article: [Kawashima, S, Togashi, Y. Resistance to immune checkpoint inhibitors and the tumor microenvironment. Exp Dermatol. 2022; 00: 1- 10. doi:10.1111/exd.14716], which has been published in final form at [https://doi.org/10.1111/exd.14716]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages there of by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.
This full-text will be available in Nov. 2023.
|
発行日 | 2022-12-08
|
出版物タイトル |
Experimental Dermatology
|
巻 | 32巻
|
号 | 3号
|
出版者 | Wiley
|
開始ページ | 240
|
終了ページ | 249
|
ISSN | 0906-6705
|
NCID | AA10958794
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
著作権者 | © 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
|
論文のバージョン | author
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.1111/exd.14716
|
Citation | Kawashima S, Togashi Y. Resistance to immune checkpoint inhibitors and the tumor microenvironment. Exp Dermatol. 2023; 32: 240-249. doi:10.1111/exd.14716
|
助成機関名 |
Japan Society for the Promotion of Science
Japan Agency for Medical Research and Development
Chiba Foundation for Health Promotion and Disease Prevention
Japan Science and Technology Agency
|
助成番号 | 20H03694
22K1945904
18cm0106340h0001
19ck0106521h0001
21cm0106383
22ck0106723h0001
21-211033868
|